The tumor suppressor candidate 3 (TUSC3) has been considered to be closely associated with the occurrence, development and invasion of various malignant tumors. However, the expression ofTUSC3in hepatocellular carcinoma (HCC) tissues remains ambiguous. The purpose of this research was to investigate the expression ofTUSC3in HCC tissues and analyze the relationship betweenTUSC3levels and clinicopathological characteristics and prognosis of HCC patients.
Immunohistochemistry was used to detect the expression ofTUSC3in HCC and the corresponding para-cancerous tissues from 92 samples of HCC patients. mRNA and protein expression levels ofTUSC3were evaluated by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot assays in 25 paired HCC and corresponding adjacent nontumor tissues. Furthermore, statistical analysis was applied to evaluate the correlation betweenTUSC3level and the clinicopathological features and prognosis of HCC patients.
Immunohistochemical assay indicated that the expression ofTUSC3was significantly lower in HCC tissues when compared with the corresponding para-cancerous tissues (χ2=11.512,P=0.001). The analysis of clinicopathological characteristics showed that low expression ofTUSC3in HCC tissues was significantly associated with Edmondson grade, Barcelona Clinic Liver Cancer stage and tumor size (P=0.008, 0.009 and 0.020, respectively). Univariate analysis showed that the expression ofTUSC3was strongly correlated with overall survival (OS) and disease-free survival (DFS) after radical surgery in HCC patients (P<0.001,P<0.001, respectively). Multivariate analysis revealed that theTUSC3level was an independent risk factor for OS and DFS in HCC patients (P=0.001,P<0.001, respectively). Results of qRT-PCR and Western blot assays indicated that the level ofTUSC3in HCC tissues was significantly lower than that in the corresponding adjacent noncancerous tissues (P<0.01,P<0.001).
The expression ofTUSC3in HCC was significantly downregulated and was correlated with tumor progression and prognosis, which could be used as an independent predictor of prognosis in HCC patients.